PATH vs SER
Uipath Inc (PATH) versus Serina Therapeutics Inc (SER) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Serina Therapeutics Inc (SER) is a biotechnology company listed on AMEX.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported SER revenue for 2024-12-31 was $56.0K. Net income was -$11.2M. Revenue was down 98.2% from 2023-12-31 to 2024-12-31. SER currently screens at market cap $29.7M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. SER currently screens at market cap $29.7M.
Not investment advice. Open the PATH and SER stock pages for the full models.
Not investment advice.